Delving into the Latest Updates on NeurOp, Inc. with Synapse

Overview

Basic Info

Introduction

NeurOp is a biopharmaceutical company that specializes in the development of new medications for central nervous system disorders such as depression, neuropathic pain, ischemia, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company was established in 2002 by Raymond Dingledine, James McNamara, and Stephen Traynelis and is based in Atlanta, Georgia. NeurOp produces and distributes pharmaceutical products as part of its operations.

NP10679 is a context-dependent and subunit-selective neg. allosteric modulator of N-methyl-D-aspartate (NMDA) receptors.It is a more potent inhibitor of GluN2B-containing NMDA receptors at the acidic levels of extracellular pH (eg, 6.9) found in the penumbral regions associated with cerebral ischemia than at physiol. pH.This property allows NP10679 to act selectively in ischemic tissue while minimizing the nonselective blockade of NMDA receptors in healthy brain, thereby reducing on-target adverse effects.We report the results of a first-in-human pharmacokinetic and safety phase 1 clin. trial in healthy volunteers receiving single or multiple doses of NP10679 (NCT04007263).We found that NP10679 was well-tolerated and with a half-life of 20 h, which is amenable to once per day dosing.The only notable side effect in this clin. trial was modest somnolence at higher doses, atypical in that the subject could easily be aroused.The overall results suggest that NP10679 is a candidate for further development for use in acute brain injury, such as ischemic stroke or aneurysmal subarachnoid hemorrhage, as well as for use in neuropsychiatric indications.

100 Deals associated with NeurOp, Inc.

Login to view more data

100 Translational Medicine associated with NeurOp, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data